期刊
ONCOIMMUNOLOGY
卷 2, 期 7, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.24850
关键词
GM-CSF; IFN; IL-2; TGF; TNF; chemokines
资金
- European Commission (ArtForce)
- Agence National de la Recherche (ANR)
- Ligue Nationale contre le Cancer
- Fondation pour la Recherche Medicale (FRM)
- Institut National du Cancer (INCa)
- Association pour la Recherche sur le Cancer (ARC), LabEx Immuno-Oncologie
- Fondation de France
- Fondation Bettencourt-Schueller
- AXA Chair for Longevity Research
- Canceropole Ile-de-France, Paris Alliance of Cancer Research Institutes (PACRI)
- Cancer Research for Personalized Medicine (CARPEM)
During the past two decades, the notion that cancer would merely constitute a cell-intrinsic disease has gradually been complemented by a model postulating that the immune system plays a relevant role during all stages of oncogenesis and tumor progression. Along with this conceptual shift, several strategies have been devised to stimulate tumor-specific immune responses, including relatively unselective approaches such as the systemic administration of adjuvants or immunomodulatory cytokines. One year ago, in the July issue of OncoImmunology, we described the main biological features of this large group of proteins and discussed the progress of ongoing clinical studies evaluating their safety and therapeutic potential in cancer patients. Here, we summarize the latest developments in this area of clinical research, focusing on high impact studies that have been published during the last 13 mo and clinical trials launched in the same period to investigate which cytokines can be employed as safe and efficient immunostimulatory interventions against cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据